Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

treatment outcome

  • Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea
    Clinical Therapeutics
    Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea

    No studies have investigated whether the discontinuation of ethambutol (EMB) based on susceptibility to isoniazid and rifampin, as determined by the GenoType MTBDRplus assay, would be appropriate. We aimed to determine the feasibility of discontinuing EMB before the end of the intensive phase of treatment based on the results of the MTBDRplus assay in patients with pulmonary tuberculosis (PTB).

    Kyung-Wook Jo, Mihye Kim, Ye-Jee Kim, Hyun-Kyung Lee, Hyun Kuk Kim, Doosoo Jeon, Jiwon Lyu, Hye Kyeong Park, Jeongha Mok, Ju Sang Kim, Eun Young Heo, Sang Bong Choi, Jae-Joon Yim, Tae Sun Shim
  • <em>In Vitro</em> MIC Values of Rifampin and Ethambutol and Treatment Outcome in <span class="named-content genus-species" id="named-content-1">Mycobacterium avium</span> Complex Lung Disease
    Clinical Therapeutics
    In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease

    Although it is known that the in vitro MICs of rifampin and ethambutol are poorly correlated with the clinical response in Mycobacterium avium complex (MAC) lung disease (MAC-LD), evidence for this is limited. This study investigated the association between treatment outcome and the in vitro MICs of rifampin and ethambutol in patients with MAC-LD....

    Byoung Soo Kwon, Mi-Na Kim, Heungsup Sung, Younsuck Koh, Woo-Sung Kim, Jin-Woo Song, Yeon-Mok Oh, Sang-Do Lee, Sei Won Lee, Jae-Seung Lee, Chae-Man Lim, Chang-Min Choi, Jin-Won Huh, Sang-Bum Hong, Sojung Park, Tae Sun Shim, Yong Pil Chong, Kyung-Wook Jo
  • Open Access
    Clinical Therapeutics
    The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease
    Qi Guo, Haiqing Chu, Meiping Ye, Zhemin Zhang, Bing Li, Shiyi Yang, Wei Ma, Fangyou Yu
  • Clinical Therapeutics
    Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis
    Hyun Lee, Soohyun Ahn, Na Young Hwang, Kyeongman Jeon, O Jung Kwon, Hee Jae Huh, Nam Yong Lee, Chang-Ki Kim, Won-Jung Koh
  • Clinical Therapeutics
    Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease
    Byung Woo Jhun, Seong Mi Moon, Su-Young Kim, Hye Yun Park, Kyeongman Jeon, O Jung Kwon, Hee Jae Huh, Chang-Seok Ki, Nam Yong Lee, Myung Jin Chung, Kyung Soo Lee, Sung Jae Shin, Charles L. Daley, Won-Jung Koh
  • Clinical Therapeutics
    Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients
    Zahra Hashemizadeh, Parisa Badiee, Seyed Ali Malekhoseini, Hadi Raeisi Shahraki, Bita Geramizadeh, Hashem Montaseri
  • Clinical Therapeutics
    Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain
    Bas C. Mourik, Gerjo J. de Knegt, Annelies Verbon, Johan W. Mouton, Hannelore I. Bax, Jurriaan E. M. de Steenwinkel
  • Clinical Therapeutics
    Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease
    Bumhee Yang, Byung Woo Jhun, Seong Mi Moon, Hyun Lee, Hye Yun Park, Kyeongman Jeon, Dae Hun Kim, Su-Young Kim, Sung Jae Shin, Charles L. Daley, Won-Jung Koh
  • Pharmacology
    Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India
    Geetha Ramachandran, Hemanth Kumar Agibothu Kupparam, Chandrasekaran Vedhachalam, Kannan Thiruvengadam, Vijayalakshmi Rajagandhi, Azger Dusthackeer, Ramesh Karunaianantham, Lavanya Jayapal, Soumya Swaminathan
  • Clinical Therapeutics
    Enterobacteriaceae Bloodstream Infections: Presence of Integrons, Risk Factors, and Outcome
    George L. Daikos, Chris Kosmidis, Panayotis T. Tassios, George Petrikkos, Alexandra Vasilakopoulou, Mina Psychogiou, Ioanna Stefanou, Athina Avlami, Nikolaos Katsilambros
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596